Gilenya was first approved in 2010 and has been a big brand for Novartis, although it is facing strong competition from newer drugs such as Roche's Ocrevus (ocrelizumab), Merck KGaA's Mavenclad ...

Gilenya is Novartis' third-biggest product and the top seller in its neuroscience franchise, bringing in revenues of almost $2.8 billion in 2021, although sales have started to decline due to ...

These drugs are believed to work by trapping specific immune system cells in the lymph nodes, preventing them from entering the brain and spinal cord. Gilenya and Tascenso ODT are approved to treat ...

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...

An Ocerevus infusion is an alternative. Oral DMTs are a good option for people who can't tolerate or don't benefit from injectable DMTs. Gilenya and Tascenso ODT (fingolimod) are pills that you take ...

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...

Introduction Long-term population-based safety studies, applying advanced causal inference techniques, including an active comparator with new-user design, are needed to investigate skin cancer ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China ...

Judith A. Waltz, JD, Diane Ung, JD, Mary Ellen Allen, JD ...